FDA plans ultra-fast review of three psychedelic drugs following Trump directive MATTHEW PERRONE Fri, April 24, 2026 at [View all]

WASHINGTON (AP) — The Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest step by the Trump administration toward possible approval of the experimental treatments.

President Donald Trump signed an executive order last weekend directing the FDA and other federal agencies to speed research and loosen restrictions on psychedelics, a class of hallucinogenic drugs which remain illegal under federal law.

The FDA said it awarded priority review vouchers to two companies studying psilocybin — the active ingredient in magic mushrooms — for hard-to-treat forms of depression. A third company received a voucher for methylone, a drug related to MDMA, for post-traumatic stress disorder. The FDA did not name the companies in a press release announcing the news.

“We owe it to our nation’s veterans and all Americans who are suffering from these conditions to evaluate these potential therapies with urgency,” FDA Commissioner Marty Makary said in a statement.

https://www.yahoo.com/news/articles/fda-plans-ultra-fast-review-140444078.html

Oh pick me, pick me. Don jr